Literature DB >> 18560263

Normal age-dependent values of serum insulin growth factor-I: results from a healthy Italian population.

G Aimaretti1, M Boschetti, G Corneli, V Gasco, D Valle, M Borsotti, A Rossi, A Barreca, L Fazzuoli, D Ferone, E Ghigo, F Minuto.   

Abstract

Serum IGF-I levels were measured in 547 non-hypopituitaric, non-acromegalic healthy subjects of both sexes in Italy to develop reference values in relation to age and sex. Participant subjects were stratified in three age classes (25- 39, 40-59 and >or=60 yr) and IGF-I assay was carried out by double-antibody radio immunoassay. Pearson's correlation coefficient between age and IGF-I values was calculated by sex and predefined age ranges. IGF-I levels significantly decreased with age (p<0.001, Kruskal-Wallis test) while sex was not a significant factor. The median IGF-I levels were 206 ng/ml in the 25-39 yr range, 147 ng/ml in the 40-59 yr range and 103 ng/ml in the >or=60 yr range. Pearson's correlation coefficient confirmed the negative correlation between age and IGF-I levels in the total sample of subjects (r=-0.529). The r coefficient between age and IGF-I levels did not differ between sexes (r=-0.570 in males and r=-0.529 in females), thus reflecting no sex-effect on IGF-I levels decline over years. No correlations were found in the 25-39 yr range (r=-0.036) or in the 40-59 yr range (r=-0.080) either, while in subjects aged >60 yr, IGF-I levels tended to further decrease with increased age (r=0.389). Ranges of normal values set at the 2.5th-97.5th percentile in the three age ranges were 95.6-366.7 ng/ml between 25 and 39 yr, 60.8-297.7 ng/ml between 40 and 59 yr and 34.5-219.8 ng/ml in subjects aged >or=60 yr. This study may contribute to the development of age-specific reference ranges for IGF-I determination in serum of normal subjects of both sexes in Italy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18560263     DOI: 10.1007/BF03346389

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  31 in total

1.  Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society.

Authors: 
Journal:  J Clin Endocrinol Metab       Date:  2000-11       Impact factor: 5.958

2.  Diagnostic efficiency of serum IGF-I, IGF-binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and urinary GH measurements in the diagnosis of adult GH deficiency: importance of an appropriate reference population.

Authors:  M L Granada; J Murillo; A Lucas; I Salinas; M A Llopis; I Castells; M Foz; A Sanmartí
Journal:  Eur J Endocrinol       Date:  2000-03       Impact factor: 6.664

3.  Serum insulin-like growth factor-I measurement in the follow-up of treated acromegaly: comparison of four immunoassays.

Authors:  C Massart; J Y Poirier
Journal:  Clin Chim Acta       Date:  2006-05-24       Impact factor: 3.786

Review 4.  Radioimmunoassays for IGFs and IGFBPs.

Authors:  W F Blum; B H Breier
Journal:  Growth Regul       Date:  1994-02

Review 5.  Clinical utility of measurements of insulin-like growth factor 1.

Authors:  David R Clemmons
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2006-08

6.  Growth hormone (GH) provocative retesting of 108 young adults with childhood-onset GH deficiency and the diagnostic value of insulin-like growth factor I (IGF-I) and IGF-binding protein-3.

Authors:  A Juul; K W Kastrup; S A Pedersen; N E Skakkebaek
Journal:  J Clin Endocrinol Metab       Date:  1997-04       Impact factor: 5.958

7.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

Review 8.  Nutritional regulation of the insulin-like growth factors.

Authors:  J P Thissen; J M Ketelslegers; L E Underwood
Journal:  Endocr Rev       Date:  1994-02       Impact factor: 19.871

9.  Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol-extracted serum.

Authors:  W H Daughaday; I K Mariz; S L Blethen
Journal:  J Clin Endocrinol Metab       Date:  1980-10       Impact factor: 5.958

10.  Reference levels of insulin-like growth factor I in the serum of healthy adults: comparison of four immunoassays.

Authors:  Michael Bernd Ranke; Karl Josef Osterziel; Roland Schweizer; Burkhardt Schuett; Karin Weber; Patricia Röbbel; Arnold Vornwald; Gunnar Blumenstock; Martin W Elmlinger
Journal:  Clin Chem Lab Med       Date:  2003-10       Impact factor: 3.694

View more
  16 in total

1.  Vitamin D status may contribute to serum insulin-like growth factor I concentrations in healthy subjects.

Authors:  F Bogazzi; G Rossi; M Lombardi; L Tomisti; C Sardella; L Manetti; O Curzio; C Marcocci; L Grasso; M Gasperi; E Martino
Journal:  J Endocrinol Invest       Date:  2010-07-29       Impact factor: 4.256

2.  Untreated adult GH deficiency is not associated with the development of metabolic risk factors: a long-term observational study.

Authors:  V Gasco; L Roncoroni; M Zavattaro; C Bona; A Berton; E Ghigo; M Maccario; S Grottoli
Journal:  J Endocrinol Invest       Date:  2019-08-22       Impact factor: 4.256

3.  Benefits of dual-release hydrocortisone treatment on central adiposity and health-related quality of life in secondary adrenal insufficiency.

Authors:  M Maccario; R Giordano; V Gasco; J Giannelli; L Campioni; E Arvat; E Ghigo; S Grottoli
Journal:  J Endocrinol Invest       Date:  2022-10-17       Impact factor: 5.467

4.  Assessment of age-related changes in heritability and IGF-1 gene effect on circulating IGF-1 levels.

Authors:  Liran Franco; Frances M K Williams; Svetlana Trofimov; Ida Malkin; Gabriela Surdulescu; Timothy Spector; Gregory Livshits
Journal:  Age (Dordr)       Date:  2014-02-04

5.  One-year GH replacement therapy reduces early cardiac target organ damage (TOD) in adult GHD patients.

Authors:  Mara Boschetti; Sergio Agosti; Valeria Albanese; Laura Casalino; Claudia Teti; Gian Paolo Bezante; Claudio Brunelli; Manuela Albertelli; Diego Ferone
Journal:  Endocrine       Date:  2016-04-13       Impact factor: 3.633

6.  Does Insulin Like Growth Factor-1 (IGF-1) Deficiency Have a "Protective" Role in the Development of Diabetic Retinopathy in Thalassamia Major Patients?

Authors:  Vincenzo De Sanctis; Carlo Incorvaia; Ashraf T Soliman; Giancarlo Candini; Alessia Pepe; Christos Kattamis; Nada A Soliman; Heba Elsedfy; Mohamed El Kholy
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-05-20       Impact factor: 2.576

7.  Liver Iron Concentration and Liver Impairment in Relation to Serum IGF-1 Levels in Thalassaemia Major Patients: A Retrospective Study.

Authors:  Vincenzo De Sanctis; Ashraf T Soliman; Giancarlo Candini; Christos Kattamis; Giuseppe Raiola; Heba Elsedfy
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-02-20       Impact factor: 2.576

8.  Clinical and Biochemical Data of Adult Thalassemia Major patients (TM) with Multiple Endocrine Complications (MEC) versus TM Patients with Normal Endocrine Functions: A long-term Retrospective Study (40 years) in a Tertiary Care Center in Italy.

Authors:  Vincenzo De Sanctis; Heba Elsedfy; Ashraf T Soliman; Ihab Zaki Elhakim; Christos Kattamis; Nada A Soliman; Rania Elalaily
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-04-12       Impact factor: 2.576

9.  Low circulating IGF-I bioactivity is associated with human longevity: findings in centenarians' offspring.

Authors:  Giovanni Vitale; Michael P Brugts; Giulia Ogliari; Davide Castaldi; Letizia M Fatti; Aimee J Varewijck; Steven W Lamberts; Daniela Monti; Laura Bucci; Elisa Cevenini; Francesco Cavagnini; Claudio Franceschi; Leo J Hofland; Daniela Mari; Joseph Janssen
Journal:  Aging (Albany NY)       Date:  2012-09       Impact factor: 5.682

10.  Insulin-like growth factor-1 as a prognostic marker in patients with acute ischemic stroke.

Authors:  Jian-Hua Tang; Li-Li Ma; Tian-Xia Yu; Juan Zheng; Hui-Juan Zhang; Hui Liang; Peng Shao
Journal:  PLoS One       Date:  2014-06-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.